1-4 July 2020 Barcelona
![]() |
![]() |
![]() |
![]() |
O-001 | PanCO: Updated Results of an Open-Label, Single-Arm Pilot Study of OncoSil P-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) With Gemcitabine Nab-Paclitaxel or FOLFIRINOX Chemotherapy | David Turner | ![]() |
![]() |
|||
LBA-001 | First-line liposomal irinotecan 5 fluorouracil/leucovorin oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study | Amie Hedges | ![]() |
![]() |
|||
P-001 | LINC00184 promotes the stemness and chemoresistance of gastric cancer by interacting with YAP and by promoting exosomes-mediated macrophage M2 polarization | Haiyan Piao | ![]() |
![]() |
|||
SO-001 | Prognostic nomogram to predict overall survival in patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: Real-world results from the multicenter retrospective study (NAPOLEON study) | Taro Shibuki | ![]() |
![]() |
|||
P-002 | An update on the trends for hepatic cancer subtypes in the Philippines, 2003-2012: A population-based study | Jansen Cambia | ![]() |
![]() |
|||
PD-002 | Role of pretreatment SUVmax on 18F-FDG PET and clinicopathological features in the prognostic stratification of newly diagnosed intrahepatic cholangiocarcinoma | Alessandro Rizzo | ![]() |
![]() |
|||
LBA-003 | CheckMate 459: Long-Term Efficacy Outcomes With Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma | Onaisa Rizki | ![]() |
![]() |
|||
SO-003 | Maintenance olaparib in patients aged &8805; 65 years with a germline BRCA mutation and metastatic pancreatic cancer: Phase 3 POLO trial | Hedy Kindler | ![]() |
![]() |
|||
P-003 | Features of metabolic profiles of blood serum and erythrocyte membranes associated with metastasis in colorectal cancer | Margarita Kruchinina | ![]() |
![]() |
|||
LBA-004 | Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer | YU SUNAKAWA | ![]() |
![]() |
|||
LBA-005 | ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600Emutant metastatic colorectal cancer | Axel Grothey | ![]() |
![]() |
|||
O-005 | Efficacy and safety of nivolumab ipilimumab in Asian patients with advanced hepatocellular carcinoma: subanalysis of the CheckMate 040 study | Onaisa Rizki | ![]() |
![]() |
|||
PD-005 | Impact of biliary drainage for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel: Results from the NAPOLEON study | Takuya Honda | ![]() |
![]() |
|||
P-005 | Economic Burden of HCC And The Need Of Innovative Treatments | Abdalla Abotaleb | ![]() |
![]() |
|||
SO-006 | The influence of liver function on the outcomes of phase II trial of sorafenib vs. hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma | Satoshi Kobayashi | ![]() |
![]() |
|||
P-006 | Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase | ERCAN ZDEN | ![]() |
![]() |
|||
PD-006 | Gemcitabine nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study | Sonia Zaibet | ![]() |
![]() |
|||
O-006 | The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma | Bruno Sangro | ![]() |
![]() |
|||
LBA-007 | Encorafenib Plus Cetuximab With or Without Binimetinib for BRAFV600E Metastatic Colorectal Cancer (mCRC): Relationship Between Carcinoembryonic Antigen (CEA) and Clinical Outcomes From BEACON CRC | Kristen Senn | ![]() |
![]() |
|||
PD-007 | Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer | Per Pfeiffer | ![]() |
![]() |
|||
P-007 | Induction chemotherapy in locally advanced rectal cancer: Retrospective report of efficacy and safety in an Argentinean university institution, a feasibility perspective | M. Celeste Diaz | ![]() |
![]() |
|||
SO-007 | Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial | Huiying Gu | ![]() |
![]() |
|||
P-008 | Risk factors of severe gastric dysplasia and gastric cancer in rural areas of China among individuals at high-risk: A population-based, cross-sectional study | Maomao Cao | ![]() |
![]() |
|||
O-008 | Atezolizumab bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 | Daneng Li | ![]() |
![]() |
|||
SO-009 | Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo | Donna Stefanoni | ![]() |
![]() |
|||
P-009 | A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer | Said Belhadef | ![]() |
![]() |
|||
P-010 | Epidemiological and histopathological review of colorectal cancer in Tunisia | sonia Ben Nasr | ![]() |
![]() |
|||
PD-010 | Improvement of Asia-Pacific colorectal screening score combined with fecal immunochemical testing at adjusted thresholds in colorectal cancer screening | Ming Lu | ![]() |
![]() |
|||
P-011 | Impact of preoperative and postoperative variation of CEA in predicting nonmetastatic colorectal cancer recurrence. | sonia Ben Nasr | ![]() |
![]() |
|||
PD-011 | Impact of baseline symptom burden as assessed by patient-reported outcomes on overall survival of patients with metastatic gastrointestinal cancer | Atul Batra | ![]() |
![]() |
|||
PD-012 | Clinical, pathological and molecular profiles of G3 neuroendocrine tumors and neuroendocrine carcinomas | Rodrigo Taboada | ![]() |
![]() |
|||
P-012 | A descriptive analysis of patient characteristics from Russian internet postings focused on CRC (iPatient study) | Alexandr Krotkevich | ![]() |
![]() |
|||
P-013 | Current and expected future profile changes of gastric and pancreatic cancer patients at presentation | Rasha Aboelhassan | ![]() |
![]() |
|||
O-014 | Young adults with neuroendocrine tumors present a high rate of pathogenic or likely pathogenic germline variants in cancer-predisposing genes | Rachel Riechelmann | ![]() |
![]() |
|||
P-014 | Dose escalated short-course radiotherapy in rectal cancers: Is this the way forward? | Deep Chakrabarti | ![]() |
![]() |
|||
SO-015 | Radiomic signature for prediction of peritoneal disseminations in gastric cancer which were not detected by routine CT examinations | Sayuri Konishi | ![]() |
![]() |
|||
P-15 | Combined Gastrectomies: Survival Outcomes in Patients with Local Advanced Gastric Cancer | Oleg Kshivets | ![]() |
![]() |
|||
P-017 | Peri-operative FLOT: West of Scotland regional experience | Katharine Welsh | ![]() |
![]() |
|||
SO-018 | Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial | Pia Osterlund | ![]() |
![]() |
|||
P-018 | REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer | Hiromichi Nakajima | ![]() |
![]() |
|||
O-018 | Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study | Carlotta Antoniotti | ![]() |
![]() |
|||
O-019 | Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors | Pia Osterlund | ![]() |
![]() |
|||
P-019 | Role of percutaneous radiofrequency ablation in unresectable, non-metastatic intrahepatic cholangiocarcinoma: A single-institution experience | Alessandro Rizzo | ![]() |
![]() |
|||
SO-020 | Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study | BEATRICE BORELLI | ![]() |
![]() |
|||
P-020 | Identification of predictive biomarkers in colorectal adenocarcinoma | Lyudmila Akhmaltdinova | ![]() |
![]() |
|||
P-021 | Stereotactic body radiation therapy for locally advanced pancreatic cancer | Maria Veronica Vera Merino | ![]() |
![]() |
|||
SO-021 | Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study) | Kristen Senn | ![]() |
![]() |
|||
O-021 | METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites | Yoshinori Kagawa | ![]() |
![]() |
|||
SO-022 | Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries | Emerik Osterlund | ![]() |
![]() |
|||
P-022 | Efficacy of sorafenib in treatment of advanced hepatocellular carcinoma in the Mexican population: Evidence from a third level hospital in Mexico | abdel dip | ![]() |
![]() |
|||
P-023 | Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials | Alessandro Rizzo | ![]() |
![]() |
|||
SO-024 | AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial | John Strickler | ![]() |
![]() |
|||
P-024 | Neutrophil and lymphocyte ratio as a prognostic biomarker in pancreatic cancer | Francine Luiz | ![]() |
![]() |
|||
P-025 | Single-institution experience of total neoadjuvant therapy for locally advanced rectal cancer: Long-term results | Roberto Milazzotto | ![]() |
![]() |
|||
SO-025 | A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701) | Toshiki Masuishi | ![]() |
![]() |
|||
P-026 | RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma | Markus Moehler | ![]() |
![]() |
|||
P-027 | Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients | Riccardo Giampieri | ![]() |
![]() |
|||
P-028 | Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma | Hossein Taghizadeh | ![]() |
![]() |
|||
P-029 | Molecular profiling of neuroendocrine tumors | Alina Isiangulova | ![]() |
![]() |
|||
P-030 | Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer | Mahmoud Elshenawy | ![]() |
![]() |
|||
SO-031 | Centralization of care leads to optimal ion and outcomes for patients with peritoneal metastases of colorectal cancer: The Catalonian regional program experience | Maria Isabel Ramos | ![]() |
![]() |
|||
P-033 | Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study | Nikolay Conev | ![]() |
![]() |
|||
SO-033 | Clonal ion of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy | Alexander Baraniskin | ![]() |
![]() |
|||
P-034 | The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy | Markus Moehler | ![]() |
![]() |
|||
P-035 | Prognostic value of ALBI score in patients with hepatocellular carcinoma Child-Pugh A | Ana Raquel Monteiro | ![]() |
![]() |
|||
P-036 | Prognostic value of tumor laterality and recurrence risk in patients with stage III colon cancer treated with adjuvant chemotherapy | Ana Raquel Monteiro | ![]() |
![]() |
|||
P-037 | Phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study | MASAHITO KOTAKA | ![]() |
![]() |
|||
SO-037 | Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504) | SATOSHI YUKI | ![]() |
![]() |
|||
P-038 | KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma | Josep Tabernero | ![]() |
![]() |
|||
P-039 | Prognostic impact of the number of administrations of oxaliplatin in the adjuvant treatment of stage III colon cancer | Joana Reis | ![]() |
![]() |
|||
P-040 | A correlation between BCL-2 modifying factor, p53 and livin gene expressions in cancer colon patients | Enas Elkhouly | ![]() |
![]() |
|||
P-041 | Understanding the clinical profiles that influence the concordance of RAS mutations between blood and tissue to guide therapy in metastatic colorectal cancer | Elena Brozos-Vázquez | ![]() |
![]() |
|||
P-042 | Primary malignant melanoma of anorectal region: An institutional experience in AIIMS Patna | JAGJIT PANDEY | ![]() |
![]() |
|||
P-043 | Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study | Maria Ortega | ![]() |
![]() |
|||
P-044 | Transcatheter arterial chemoembolization using CDDP without Lipiodol for super-elderly patients with hepatocellular carcinoma | Takeshi Aramaki | ![]() |
![]() |
|||
P-045 | Applicable value of transanal endoscopic microsurgery for high-risk rectal adenoma and early rectal cancer: Experience from 126 cases | Yunhao Li | ![]() |
![]() |
|||
P-046 | Advanced colorectal adenoma detection based on altered methylation signal in plasma samples | Kristi Kruusmaa | ![]() |
![]() |
|||
P-047 | A phase I/II study of pembrolizumab in combination with ibrutinib for advanced, refractory microsatellite stable colorectal cancers | Elaine Tan | ![]() |
![]() |
|||
P-048 | First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer | Hossein Taghizadeh | ![]() |
![]() |
|||
P-049 | A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study | Erika Martinelli | ![]() |
![]() |
|||
P-050 | Safety and tolerability of regorafenib: A real-life experience | Youssif Abo Elseud | ![]() |
![]() |
|||
P-051 | Immunoscore in rectal cancer patients receiving radiation followed by mFOLFOX with avelumab | Ali Shamseddine | ![]() |
![]() |
|||
P-052 | The diagnostic dilemma between chronic pancreatitis and pancreatic cancer | Turon Mirzaev | ![]() |
![]() |
|||
P-053 | Clinical evaluation of complex treatment of colorectal cancer with liver metastases | Marufjon Salokhiddinov | ![]() |
![]() |
|||
P-054 | BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal | Rachel Riechelmann | ![]() |
![]() |
|||
P-055 | GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells | Rachel Riechelmann | ![]() |
![]() |
|||
P-056 | Importance determination of interleukin-6 in bile and blood in tumours of the bileopancreatoduodenal zone | Marufjon Salokhiddinov | ![]() |
![]() |
|||
P-058 | Survival and prognostic factors in metastatic gastric cancer: results from a Bangladeshi cohort | Md Shuayb | ![]() |
![]() |
|||
P-059 | High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer | Ryoichi Sawada | ![]() |
![]() |
|||
P-061 | nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life | Esther Una Cidon | ![]() |
![]() |
|||
P-062 | Inferior survival for mismatch repair deficient metastatic colorectal cancer observed in an Irish cohort | Alice Talbot | ![]() |
![]() |
|||
P-063 | FOLFIRINOX in borderline resectable pancreatic carcinoma | Esther Una Cidon | ![]() |
![]() |
|||
P-064 | P-in and factor VIII as risk factors of thromboembolic disease in patients with hepatocellular carcinoma | Matej Hrncar | ![]() |
![]() |
|||
P-065 | Locally advanced/metastatic gastric cancer: Real-world data on first-line treatment with oxaliplatin and cisplatin-based doublets | Helena Luna Pais | ![]() |
![]() |
|||
P-066 | Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population | Gabriella Buccafusca | ![]() |
![]() |
|||
P-067 | Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advance gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial | Yongjia Yan | ![]() |
![]() |
|||
P-069 | Efficacy and safety of S-1 following gemcitabine plus cisplatin for biliary tract cancer | Hiroto Inoue | ![]() |
![]() |
|||
P-070 | Multimodal treatment in metastatic colorectal cancer improves outcomes: a University College London Hospital experience | Nalinie Joharatnam-Hogan | ![]() |
![]() |
|||
P-071 | Prognostic biomarkers of therapy by hepatic radioembolization with Ytrio-90 spheres in colorectal liver metastases | Eva M Triviño-Ibáñez | ![]() |
![]() |
|||
P-072 | Biomarkers of survival and therapeutic response to hepatic radioembolization with Ytrio-90 spheres in hepatocellular carcinoma | Eva M Triviño-Ibáñez | ![]() |
![]() |
|||
P-073 | Clinical prognostic factors for overall survival and time to progression in RAS-wild type metastatic colorectal cancer treated with anti-EGFR monoclonal antibodies as third or subsequent-line therapy | Tomasz Lewandowski | ![]() |
![]() |
|||
P-075 | Retrospective comparison between FLOT perioperative chemotherapy vs surgery followed by adjuvant chemotherapy: Results from a multicenter analysis | Maria Giuditta Baleani | ![]() |
![]() |
|||
P-076 | A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer | Samantha Nguyen | ![]() |
![]() |
|||
P-077 | Real-world evidence on second-line treatment of fluoropyrimidine, irinotecan, and anti-VEGF antibody for metastatic colorectal cancer | Takeharu Yamanaka | ![]() |
![]() |
|||
P-078 | Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies | Emma McConnell | ![]() |
![]() |
|||
P-079 | C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens | Marianna Luciana Ferrara | ![]() |
![]() |
|||
P-080 | TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma | Pascal Hammel | ![]() |
![]() |
|||
P-081 | Phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22 | Mitsumi Terada | ![]() |
![]() |
|||
P-082 | Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer | Hironaga Satake | ![]() |
![]() |
|||
P-083 | Pancreatic cancer, treatment options, and sequential therapy: The experience of a district oncology center | Alícia Oliveira | ![]() |
![]() |
|||
P-084 | Colon cancer in the elderly: A comprehensive assessment of treatment and its outcomes | Alícia Oliveira | ![]() |
![]() |
|||
P-086 | Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial | Feng Bi | ![]() |
![]() |
|||
P-088 | A multicenter analysis of the correlation between overall survival and progression-free survival and the number of chemotherapeutic key drugs used in patients with advanced/unresectable pancreatic cancer: Results from the NAPOLEON study | Tsuyoshi Shirakawa | ![]() |
![]() |
|||
P-089 | Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy | Juan Ruiz Bañobre | ![]() |
![]() |
|||
P-090 | Does the postoperative course of events influence 2-year mortality in patients undergoing hyperthermic intraperitoneal chemotherapy? An evaluation by a novel scoring system | Mrudula Tatakuri | ![]() |
![]() |
|||
P-091 | A retrospective analysis of maintenance strategies in metastatic gastric and gastroesophageal cancer | Daniel Walden | ![]() |
![]() |
|||
P-092 | Autophagy drugs are dynamic regulators of long non-coding RNA expression in colorectal cancer | Md Zahirul Islam Khan | ![]() |
![]() |
|||
P-093 | Levels of steroid hormones, their precursors and ACTH in the blood of patients with pancreatic diseases | Olesia Ossovskaya | ![]() |
![]() |
|||
P-094 | Predictive assessment of peritoneal spread in patients with gastric cancer | Elena Frantsiyants | ![]() |
![]() |
|||
P-095 | Non-metastatic anal cancer outcomes: A single-center experience | Diana Simão | ![]() |
![]() |
|||
P-096 | Levels of sex hormones and sex steroid receptors in pathological tissues in gastric cancer patients | Olesia Ossovskaya | ![]() |
![]() |
|||
P-097 | Functions of antioxidant enzymes in the blood of patients with pancreatic neuroendocrine tumors | Olesia Ossovskaya | ![]() |
![]() |
|||
P-098 | HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer | Takayuki Ando | ![]() |
![]() |
|||
P-099 | Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: Phase 3 KEYNOTE-966 trial in progress | Arndt Vogel | ![]() |
![]() |
|||
P-100 | Quality of life assessment and reporting in gastric cancer treatment: A systematic review of phase 3 clinical trials published between 2010 and 2019 | Angela Dalia Ricci | ![]() |
![]() |
|||
P-102 | The impact of a multidisciplinary approach in the management of pancreatic disease | BRUNELLA DI STEFANO | ![]() |
![]() |
|||
P-103 | The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study. | Floriana Camarda | ![]() |
![]() |
|||
P-105 | Defining novel regulators of inflammatory signaling in pancreatic cancer | Jane Parry | ![]() |
![]() |
|||
P-106 | Liver metastasis in colorectal cancer: Management and survival outcomes of liver metastasectomy in a single-center analysis | Marta Vilaa | ![]() |
![]() |
|||
P-107 | LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment | Sadahisa Ogasawara | ![]() |
![]() |
|||
P-108 | Perioperative chemotherapy in locally advanced, resectable gastric cancer: A single-center experience | Marta Vilaa | ![]() |
![]() |
|||
P-109 | Global mortality for biliary tract cancer | Huifen Wang | ![]() |
![]() |
|||
P-111 | Prognostic value of inflammation-based scores for patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel | Shintaro Nakano | ![]() |
![]() |
|||
P-112 | HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody | Hiroshi Nakatsumi | ![]() |
![]() |
|||
P-113 | Supportive medication in advanced biliary tract cancers with ABC-02 regimen | joni howells | ![]() |
![]() |
|||
P-114 | Cytokines as a prognostic marker of overall survival in pancreatic cancer: A meta-analysis and systematic review | Harold Nathan Tan | ![]() |
![]() |
|||
P-115 | PEMREC: A phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal cancer | Thibaud Kssler | ![]() |
![]() |
|||
P-116 | Impact of the number of harvested lymph nodes on survival in Egyptian patients with gastric cancer: Middle eastern tertiary center experience | Hussein Fakhry | ![]() |
![]() |
|||
P-117 | Prognostic role of plasmatic exosomal and tissue caveolin-1 in metastatic pancreatic cancer patients | Alessandro Bittoni | ![]() |
![]() |
|||
P-118 | Gastroenteropancreatic neuroendocrine tumors: Experience of the oncology department of the Oran military hospital | Amir Zakaria DJOUNIDI | ![]() |
![]() |
|||
P-119 | Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes | Esther Una Cidon | ![]() |
![]() |
|||
P-120 | Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY Study in CIRCULATE-Japan (trial in progress) | Hiroki Yukami | ![]() |
![]() |
|||
P-122 | Treatment related response of T regulatory cells and cytotoxic lymphocytes in early PDAC | Skaiste Tulyte | ![]() |
![]() |
|||
P-123 | Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting. | Nieves Martinez Lago | ![]() |
![]() |
|||
P-124 | Tumor budding and CDX2 as additional prognostic factors in stage II colon cancer | Debora Ierinò | ![]() |
![]() |
|||
P-125 | Radiomic prediction model for pathological responses of neoadjuvant chemotherapy with S-1 plus oxaliplatin (G-SOX) in clinical stage III gastric cancer | Dai Manaka | ![]() |
![]() |
|||
P-126 | Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy | KONSTANTINOS KAMPOSIORAS | ![]() |
![]() |
|||
P-127 | Potential mechanism of circRNA 000585 in cholangiocarcinoma | Fengming Yi | ![]() |
![]() |
|||
P-128 | A novel combination of GEMOX and apatinib in treatment of unresectable or metastatic cholangiocellular carcinoma | Fengming Yi | ![]() |
![]() |
|||
P-129 | Camrelizumab combined with sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma: A retrospective study | Qinqin Liu | ![]() |
![]() |
|||
P-130 | Short course pelvic radiotherapy for localized and oligometastatic rectal adenocarcinoma: The Mayo Clinic experience | Shing Fung Lee | ![]() |
![]() |
|||
P-131 | Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial | Haeseong Park | ![]() |
![]() |
|||
P-132 | Malignant transformation of choledochal cysts: Description of a North African series of 7 cases | Anisse Tidjane | ![]() |
![]() |
|||
P-133 | Extramural venous invasion detected with an elastin stain is a powerful predictor of cancer-specific mortality in STAGE I-IIIB resected colorectal cancer | David Cyr | ![]() |
![]() |
|||
P-134 | Total neoadjuvant therapy in locally advanced rectal cancer patients: A tertiary medical center experience | Ali Shamseddine | ![]() |
![]() |
|||
P-136 | Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability | Teodora Kolarova | ![]() |
![]() |
|||
P-137 | High rectal cancer: Whats the best treatment? | Maria Neves | ![]() |
![]() |
|||
P-138 | A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases | Shelize Khakoo | ![]() |
![]() |
|||
P-140 | Targeted NGS panel of epigenetic regulators genes: Application results for gastric cancer patients | Alexey Kalinkin | ![]() |
![]() |
|||
P-141 | The contribution of white blood cell gene expression in the prediction of gastrointestinal cancer | Panagiotis Apostolou | ![]() |
![]() |
|||
P-142 | Early gastric cancer: Identification of molecular markers able to distinguish penetrating lesions with different prognosis | Chiara Molinari | ![]() |
![]() |
|||
P-143 | Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer | Adriana Soares | ![]() |
![]() |
|||
P-144 | Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: Phase 3 PROOF trial | Lee Miller | ![]() |
![]() |
|||
P-145 | CT-based texture analysis using radiomics for hepatic sinusoidal obstruction syndrome (HSOS) in colorectal cancer patients treated with oxaliplatin containing chemotherapy | Kiyotaka Kawaguchi | ![]() |
![]() |
|||
P-146 | A genetic custom-made in vivo drug screening platform for colorectal cancer patients | Nahuel Villegas | ![]() |
![]() |
|||
P-147 | Efficacy and safety data of trifluridine/tipiracil treatment in advanced colorectal cancer based on the experience of Juan Ramón Jiménez Hospital in Huelva | María Amor Urbano | ![]() |
![]() |
|||
P-150 | Khorana and PROTECHT scores in predicting the risk of venous thromboembolism in pancreatic cancer: Which performed better? | Sara Dmaso | ![]() |
![]() |
|||
P-151 | The impact of adjuvant chemotherapy regimens in stage II colon cancer (CC) patients | Soraia Lobo-Martins | ![]() |
![]() |
|||
P-152 | The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients | Maria Bensi | ![]() |
![]() |
|||
P-153 | Novel ultrasonographic scoring system of sinusoidal obstruction syndrome associated with oxaliplatin-based chemotherapy in patients with gastrointestinal cancer | Rika Saito | ![]() |
![]() |
|||
P-154 | Actionable targets by tumor genomic profiling in patients with cholangiocarcinoma | Lee Miller | ![]() |
![]() |
|||
P-155 | Efficacy of somatostatin analogues in the treatment of metastatic and unresectable pancreatic neuroendocrine tumors | Rafael Correa | ![]() |
![]() |
|||
P-156 | A phase Ib\II study of cetuximab and pembrolizumab in metastatic colorectal cancer | Christos Fountzilas | ![]() |
![]() |
|||
P-157 | Incidence and survival of intestinal soft tissue sarcoma: A retrospective analysis from SEER | Shuai Wang | ![]() |
![]() |
|||
P-158 | Clinical impact of oral intake in third-line treatment for advanced gastric cancer | TAKATSUGU OGATA | ![]() |
![]() |
|||
P-160 | A phase II study of resection followed capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Safety analysis | Takanori Watanabe | ![]() |
![]() |
|||
P-161 | Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients | raffaella vivolo | ![]() |
![]() |
|||
P-162 | Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer | arezki arab | ![]() |
![]() |
|||
P-163 | Systemic chemotherapy for previously treated metastatic small bowel ddenocarcinoma | Taiko Nakazawa | ![]() |
![]() |
|||
P-164 | The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel | marta chiaravalli | ![]() |
![]() |
|||
P-166 | Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics | Annunziato Anghelone | ![]() |
![]() |
|||
P-167 | Impact of testosterone on sexual function in women with rectal cancer: A prospective, longitudinal, cohort study | Annika Svanstrm Rjvall | ![]() |
![]() |
|||
P-169 | A first-in-human Phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers | James J. Harding | ![]() |
![]() |
|||
P-170 | Understanding patient experience in hepatocellular carcinoma (liver cancer): A qualitative patient interview study | Shethah Morgan | ![]() |
![]() |
|||
P-171 | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria | Takuya Sho | ![]() |
![]() |
|||
P-172 | Prognostic factors in metastatic gastric cancer patients | Élia Cipriano | ![]() |
![]() |
|||
P-173 | The role of maintenance therapy in the first and second lines of treatment of metastatic colorectal cancer | Danila Gridnev | ![]() |
![]() |
|||
P-175 | Total neoadjuvant treatment versus standard therapy (neoadjuvant radiochemotherapy and adjuvant chemotherapy) of rectal cancer with high-risk factors for local or systemic recurrence | Vaneja Velenik | ![]() |
![]() |
|||
P-176 | Epidemiology and clinical outcomes of patients with pancreatic tumors discussed in tumor board | Juliana Silva | ![]() |
![]() |
|||
P-177 | Overall survival of patients with left-sided metastatic colorectal cancer in real life: Experience from University Hospital for Tumors in Zagreb, Croatia | Mirjana Pavlovic | ![]() |
![]() |
|||
P-178 | Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis | iori motoo | ![]() |
![]() |
|||
P-179 | The screening and consensus based on practices and evidence (SCOPE) survey: Results of a real-world survey on metastatic colorectal cancer practice patterns | Joanne Franklin | ![]() |
![]() |
|||
P-181 | Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancer | Stefania Gkoura | ![]() |
![]() |
|||
P-182 | Understanding biliary tumours: Survival outcomes and prognostic factors in a single center | Diogo Silva | ![]() |
![]() |
|||
P-183 | Inflammatory Response Prediction of Systemic Therapy Outcome in Metastatic Colorectal Cancer | Amer Radwi | ![]() |
![]() |
|||
P-184 | A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma | Eric Van Cutsem | ![]() |
![]() |
|||
P-185 | Dietary factors in gastrointestinal cancers: A hospital-based case-control study | tasneef zargar | ![]() |
![]() |
|||
P-186 | Introduction of DYPD screening and its impact on treatment decisions: One centres experience | Alexander Burnett | ![]() |
![]() |
|||
P-187 | Impact on survival of local complications in pancreatic cancer: Experience at the Ramón y Cajal University Hospital (HURyC) | María San Román Gil | ![]() |
![]() |
|||
P-188 | Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients | Irene Pecora | ![]() |
![]() |
|||
P-189 | Role of radiomics in clinical prognostication and prediction of survival among a cohort of metastatic intrahepatic cholangiocarcinoma | Venkata pradeep babu koyyala | ![]() |
![]() |
|||
P-190 | A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data | Pasquale Vitale | ![]() |
![]() |
|||
P-191 | Optimal age to start screening for colorectal cancer in average-risk adults: 50 or 45 years old? | Dimitrios Tzilves | ![]() |
![]() |
|||
P-192 | ART SCORE in determining the feasibility of TACE in hepatocarcinoma | Filipa Macedo | ![]() |
![]() |
|||
P-193 | Safety, tolerability, and efficacy of total neoadjuvant therapy for adult patients with locally advanced high-risk rectal adenocarcinoma: Retrospective real-world data from South India | Ajoy John | ![]() |
![]() |
|||
P-194 | The use of cytoreduction and HIPEC in the treatment of peritoneal carcinomatosis: The experience in Ramón y Cajal University Hospital | Jorge Esteban Villarrubia | ![]() |
![]() |
|||
P-195 | Treatment outcomes of trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A single-centre observational study | Juraj Prejac | ![]() |
![]() |
|||
P-196 | CA 19-9 and CEA as markers of survival in rectal cancer | Fatima Aurora Aires | ![]() |
![]() |
|||
P-198 | The AST/ALT ratio predicts clinical outcome in pancreatic cancer patients treated with capecitabine and gemcitabine: a single institution experience in the west of Algeria | aicha bengueddach | ![]() |
![]() |
|||
P-199 | The prognostic and therapeutic impact of microsatellite instability in stage II colon cancer: Medical oncology service chu hassan II fes | SOUMIA BERRAD | ![]() |
![]() |
|||
P-200 | Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution | Emilio Francesco Giunta | ![]() |
![]() |
|||
P-201 | Neoadjuvant hypofractionated intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer | Maria Veronica Vera Merino | ![]() |
![]() |
|||
P-202 | Demographics and Clinical Characteristics of Metastatic Colorectal Cancer Patients Treated With a Biosimilar to Bevacizumab | Whitney Rhodes | ![]() |
![]() |
|||
P-203 | Restaging rectal cancer after neoadjuvant chemoradiation therapy: Is magnetic resonance imaging accurate enough? | Rita Félix Soares | ![]() |
![]() |
|||
P-204 | C60 fullerene inhibits hepatocellular carcinoma development and metastasis: in vitro and in vivo studies | Halyna Kuznietsova | ![]() |
![]() |
|||
P-205 | Could chemotherapy still be useful in Hepatocarcinoma? Experience at a single institution in Lima-Perú | Cristian Pacheco-Román | ![]() |
![]() |
|||
P-206 | Prognosis of Patients Presenting as Carcinoma of Unknown Primary and Effectiveness of Acute Oncology Service: A Single Institution Experience | Rajarshi Roy | ![]() |
![]() |
|||
P-208 | Is there a role for adjuvant chemotherapy in ypN0 disease rectal cancer patients? | Rita Félix Soares | ![]() |
![]() |
|||
P-209 | Multicenter Real Life Experience of Biological Agents in patients with Metastatic Colorectal Cancer | Duygu Cevik | ![]() |
![]() |
|||
P-210 | The outcomes and toxicity of FOLFIRINOX treatment in a cohort of patients with incurable pancreatic cancer treated in a single centre in Northern Ireland. | Olivia Devlin | ![]() |
![]() |
|||
P-211 | Prognostic value of interleukin-6 in colon cancer patients: a prospective study in 60 Tunisian patients | Ichrak Ben Abdallah | ![]() |
![]() |
|||
P-212 | Factors affecting median PFS in patients with advance, non-resectable well differentiated pancreatic neuroendocrine tumors treated initially with Octreotide LAR - real world data. . | Agnieszka Kolasi&324;ska-&262;wikla | ![]() |
![]() |
|||
P-213 | Role of reactive oxygen species, IL-6 and KRAS mutation in rectal adenocarcinoma | Luiza Serbanescu | ![]() |
![]() |
|||
P-214 | A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients | Hannah Reed | ![]() |
![]() |
|||
P-215 | Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): Interim safety analysis | Chelsea Higgins | ![]() |
![]() |
|||
P-216 | Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016) | Adelaida García Velasco | ![]() |
![]() |
|||
P-217 | Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients | Jessica Lucchetti | ![]() |
![]() |
|||
P-219 | Clear cell variant of hepatocellular carcinoma (HCC-CC): a single-center observational study of an uncommon subtype | Francesca Salani | ![]() |
![]() |
|||
P-220 | Management of colorectal cancers: improving clinical management of patients with MSI-high disease through education | KINJAL PARIKH | ![]() |
![]() |
|||
P-221 | Clinical and pathological characteristics of patients with gastrointestinal neuroendocrine tumors in the United States | Dina El-Habashy | ![]() |
![]() |
|||
P-222 | Primary malignant tumors of the small intestine: Clinical and therapeutic aspects | SOUMIA BERRAD | ![]() |
![]() |
|||
P-223 | Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy | George Papaxoinis | ![]() |
![]() |
|||
P-224 | Improving the management of patients with pancreatic cancer: Education from treatment to adverse events and coordination of care | KINJAL PARIKH | ![]() |
![]() |
|||
P-225 | KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy | Tatiana Cunha Pereira | ![]() |
![]() |
|||
P-226 | Analysis of Hispanic Latino American Patients with Colorectal Cancer, Clinical Features and Laterality as a Prognosis Factor of Overal Survival | Calderillo-Ruiz German | ![]() |
![]() |
|||
P-227 | Prognostic and predictive factors of platinum-based chemotherapy in gastroenteropancreatic neuroendocrine neoplasms G3 | Agnieszka Kolasi&324;ska-&262;wikla | ![]() |
![]() |
|||
P-228 | SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies | William Losin | ![]() |
![]() |
|||
P-229 | Elderly population do benefit from adjuvant chemotherapy in gastric cancer: Experience in a single institution | Cristian Pacheco-Román | ![]() |
![]() |
|||
P-232 | Clinical Outcomes and Characteristics According to Localization of Colorectal Cancer In Fundacion Santa Fe De Bogota Between May 2015- May 2019 | Luis Pino | ![]() |
![]() |
|||
P-233 | Metformin combined with irinotecan in patients with refractory colorectal cancer: A phase 2 trial | Raphael L. Araujo | ![]() |
![]() |
|||
P-234 | A SEER based analysis of clinical characteristics and survival in patients with functional endocrine tumors of gastrointestinal origin | Apoorva Jayarangaiah | ![]() |
![]() |
|||
P-235 | Management of constipation associated with advanced cancers, chemotherapy and opioid-induced constipation by oral herbal supplement in heterogeneous group of gastrointestinal, hepatobiliary and pancreatic cancers | Anandrao Patil | ![]() |
![]() |
|||
P-236 | New polyclonal antibody therapeutic to treat esophageal adenocarcinoma and Barretts esophagus by targeting EPHB4 | Pablo GarciaValtanen | ![]() |
![]() |
|||
P-237 | Impact of adjuvant chemotherapy in poorly cohesive gastric carcinoma: Experience from the Peruvian National Cancer Institute | Mariana Serrano | ![]() |
![]() |
|||
P-239 | Patient-reported outcomes in patients with metastatic gastric and esophageal cancers near end-of-life | Atul Batra | ![]() |
![]() |
|||
P-240 | Anal cancer treatment: Major reduction of acute toxicity with an approach using 4-fractions-per-week | Cam Nguyen | ![]() |
![]() |
|||
P-241 | First- and Second-Line treatment With Tyrosine Kinase Inhibitors After Chemoembolization In Intermediate-Stage Hepatocellular Carcinoma Patients | Dimitrios Dimitroulopoulos | ![]() |
![]() |
|||
P-242 | Germline mutations identified in Colombian patients with Lynch syndrome | John Jairo Suarez Olaya | ![]() |
![]() |
|||
P-243 | Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain | Raquel Guardeño Sánchez | ![]() |
![]() |
|||
P-244 | Demographic Data, Risk Factors, and Clinical Aspects of Hepatocellular Carcinoma (HCC) in Southeastern Europe During the Last Decade | Dimitrios Dimitroulopoulos | ![]() |
![]() |
|||
P-245 | GETNET-SILVELUL Study: An original or modified Immunohistochemical Score (IPS or mIPS) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with Everolimus or CAPTEM | Antonio Viudez | ![]() |
![]() |
|||
P-246 | Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer | Paola Di Nardo | ![]() |
![]() |
|||
P-247 | Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France. | Romain Cohen | ![]() |
![]() |
|||
P-248 | Quality of life among Tunisian gastrointestinal cancer patients undergoing chemotherapy | Ennouri Sana | ![]() |
![]() |
|||
P-249 | Resecting the unresectable: Superior survival of triple modality pancreatic adenocarcinoma patients | Yang Jian Ong | ![]() |
![]() |
|||
P-250 | Significance of microsatellite instability PCR evaluation for metastatic colorectal cancer patients: Dynamic changes during disease course (preliminary results) | Petrova Veneta | ![]() |
![]() |
|||
P-251 | Diversity of Helicobacter pylori genotypes in tumoral, adjacent and antral tissue of Colombian patients with gastric cancer | Alix Guevara | ![]() |
![]() |
|||
P-252 | Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma | Iranzu Gonzalez | ![]() |
![]() |
|||
P-254 | An experience of two Croatian centers in the treatment of gastroenteropancreatic neuroendocrine neoplasms with long-acting octreotide treatment | Borislav Belev | ![]() |
![]() |
|||
P-255 | Effects of tumor treating fields (150 kHz) in combination with FOLFOX on gastric cancer cells in vitro | Adi Haber | ![]() |
![]() |
|||
P-256 | Survival rates of locally advanced and metastatic pancreatic cancer in Western Australia | Yang Jian Ong | ![]() |
![]() |
|||
P-257 | Deep Polychromatic Flow Cytometry Characterization of Circulating Endothelial Cells in Metastatic Colorectal Cancer Patients | Davide Brocco | ![]() |
![]() |
|||
P-258 | Evaluation of volumetric modulated arc therapy with simultaneous integrated boost in carcinoma of the anal canal | Mariacarla Valli | ![]() |
![]() |
|||
P-259 | Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis | Sik Kwan Chan | ![]() |
![]() |
|||
P-260 | Nave indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer | David Turner | ![]() |
![]() |
|||
P-261 | Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma | Adi Haber | ![]() |
![]() |
|||
P-262 | Effect of neoadjuvant chemotherapy in patients with gastric cancer: A retrospective study | behourah zoubida | ![]() |
![]() |
|||
P-263 | The role of biologic targets in metastatic colorectal cancer in non-elderly patients: A single institutional analysis | Marta Peixoto | ![]() |
![]() |
|||
P-264 | Clinical validation of next-generation sequencing as a liquid biopsy for the monitoring of patients with metastatic colorectal cancer | Myrto Kastrisiou | ![]() |
![]() |
|||
P-265 | The study of mutations of the KRAS, NRAS, and BRAF genes in patients with colorectal cancer depending on gender, age, race in the population of the Republic of Kazakhstan | Yelena Ukolova | ![]() |
![]() |
|||
P-266 | LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: the LINE study | Anna Michelotti | ![]() |
![]() |
|||
P-267 | Signet-Ring Cell Carcinoma of the Colon: 10-Case Experience of the Medical Oncology Department at Hassan II University Hospital | SOUMIA BERRAD | ![]() |
![]() |
|||
P-268 | Diabetes and risk of pancreatic cancer | Alaeddine SAIDI | ![]() |
![]() |
|||
P-269 | Lenvatinib in hepatocellular carcinoma: QoL surveys and radiological imaging markers predicting clinical outcome in patients with hepatocellular carcinoma treated with lenvatinib as first-line treatment (SULENVA-HCC) | Nicoletta Zanaletti | ![]() |
![]() |
|||
P-270 | Early tumor shrinkage as a predictor of favorable outcomes in patients with unresectable metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab | behourah zoubida | ![]() |
![]() |
|||
P-271 | Meta-analyses on mutation status concordance between tumor tissue and circulating tumor DNA (ctDNA) and prognostic value of ctDNA in pancreatic cancer (PC) | Anna Popova | ![]() |
![]() |
|||
P-272 | Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy | Chiara Maddalena | ![]() |
![]() |
|||
P-273 | Real-world experience of definitive chemoradiation in esophageal cancer: Correlation of tumour length, toxicity and disease control | Rajarshi Roy | ![]() |
![]() |
|||
P-274 | RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma | Rille Pihlak | ![]() |
![]() |
|||
P-275 | Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: results from the randomised CAIRO6 trial | Checca Bakkers | ![]() |
![]() |
|||
P-276 | Neutrophil/lymphocyte ratio (NLR) predicts survival after curative treatments for rectal cancer patients | Edna Darlene Rodrigues Pinto | ![]() |
![]() |
|||
P-277 | Epidemiology of pancreatic cancer: Experience of the medical oncology department of CHU HASSAN II fez | hayat Erraichi | ![]() |
![]() |
|||
P-278 | Neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios as predictive markers of pathological response to FLOT neoadjuvant strategy in locally advanced gastric/gastroesophageal junction cancer | Tiago Cruz Tomás | ![]() |
![]() |
|||
P-279 | Clinical utility of circulating tumor DNA (ctDNA) in resectable and advanced pancreatic cancer (PC) | Anna Popova | ![]() |
![]() |
|||
P-280 | The comparison of mFOLFOX-6, mDCF, mFOLFIRINOX in the first-line treatment of advanced gastric cancer | Ekaterina Ignatova | ![]() |
![]() |
|||
P-281 | Colon Cancer in Elderly Patients: Experience of the Medical Oncology Department of CHU HASSAN II Fez | hayat Erraichi | ![]() |
![]() |
|||
P-282 | Long-term outcomes after neoadjuvant chemoradiotherapy and R0 resection in ESCC : A propensity-matched analysis of PF versus CROSS regimen | Ka-On Lam | ![]() |
![]() |
|||
P-283 | Analysis of KRAS mutation allele in circulating cell-free DNA derived from urine in colorectal cancer patients | Ryo Ohta | ![]() |
![]() |
|||
P-285 | Therapeutic management of exocrine pancreatic cancer in elderly patients | Alaeddine SAIDI | ![]() |
![]() |
|||
P-288 | Nerve fibers in the tumour microenvironment are co-localized with tertiary lymphoid structures and is associated with better survival in pancreatic cancer patients | Lara Heij | ![]() |
![]() |
|||
P-289 | Role of the neoadjuvant chemoradiotherapy in esophageal cancer: Our centers experience | Tanny Barreto | ![]() |
![]() |
|||
P-291 | Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study | Mikhail Fedyanin | ![]() |
![]() |
|||
P-292 | Locally advanced esophageal cancer: Pattern of care, treatment outcomes and prognostic factors over a 20-year experience at the Modena Cancer Centre | Fabio Canino | ![]() |
![]() |
|||
P-293 | Overall survival according to mutation frequency of BRAF, NRAS genes, and MSI status in patients with wild-type KRAS metastatic colorectal cancer treated with cetuximab | Raphael L. Araujo | ![]() |
![]() |
|||
P-294 | Incorporating genetic counseling service into the gastrointestinal tumor board: Experience, obstacles, and opportunities in a Mexican center | Guillermo Pacheco Cuellar | ![]() |
![]() |
|||
P-295 | Patterns of failure following neoadjuvant and definitive radiation strategies in carcinoma thoracic esophagus: Do we need to rethink targets? | Farhan Ahmad | ![]() |
![]() |
|||
P-296 | Chemosensitivity and Outcome in Advanced And Metastatic Gastric Signet-Ring Cell Carcinoma (GSRC) | Priscila Nejo | ![]() |
![]() |
|||
P-298 | Surgical resection of primary tumor as a prognostic factor in stage IV colon adenocarcinoma | Kanika Nair | ![]() |
![]() |
|||
P-299 | Cytoreductive surgery with gastrectomy and HIPEC for gastric cancer with limited peritoneal metastases treated with neodjuvant systemic therapy is feasible and safe | Maria Isabel Ramos | ![]() |
![]() |
|||
P-300 | Overall survival with single vs multi-agent chemotherapy in stage IIIA colon adenocarcinoma | Kanika Nair | ![]() |
![]() |
|||
P-301 | Gastrointestinal stromal tumors: 10 years of experience in the medical oncology department at Mohammed VI university hospital in Marrakech, Morocco | mohamed kaakoua | ![]() |
![]() |
|||
P-302 | Prognostic factors in stage IV appendiceal adenocarcinoma | Kanika Nair | ![]() |
![]() |
|||
P-303 | Definitive radiation for esophageal cancer: Experience of a Portuguese cancer center | Bárbara de Castro | ![]() |
![]() |
|||
P-304 | Effectiveness and safety of thermal ablation of pulmonary metastases in patients with colorectal cancer | Nishanthi Silva | ![]() |
![]() |
|||
P-305 | Efficacy and safety of IMATINIB in gastrointestinal stromal tumors: Experience of the medical oncology department of the CHU Hassan II of FES | Nouiakh Lamyae | ![]() |
![]() |
|||
P-307 | Colorectal cancer in young people under 45: Experience of the medical oncology service of the Hospital Hassan II of FEZ | Nouiakh Lamyae | ![]() |
![]() |
|||
P-309 | Correlation between baseline CEA levels and TNM stage at presentation in colorectal cancers in an Indian population | Venkata pradeep babu koyyala | ![]() |
![]() |
|||
P-311 | Low Risk of Advanced Neoplasms for up to 20 Years after Negative Colonoscopy:Potential for Personalized Follow up Screening Intervals | Thomas Heisser | ![]() |
![]() |
|||
P-312 | Perioperative Chemotherapy Versus Surgery Alone on Resectable Advanced Gastric Cancer in a Moroccan Population | siham Lalaoui Rachidi | ![]() |
![]() |
|||
P-313 | Management of frail patients with metastatic pancreatic ductal adenocarcinoma: A single-institution experience | Andrea Plaja Salarich | ![]() |
![]() |
|||
P-314 | Supine VMAT versus prone 3D-EBRT in preoperative rectal cancer: Dosimetric comparison and pathological response with each radiotherapy technique | Laura Diaz | ![]() |
![]() |
|||
P-315 | Impact of tumor location (right vs left) as a prognostic and predictive factor in colon cancer in a Moroccan population: A single-center study | Nada Benhima | ![]() |
![]() |
|||
P-317 | Survival outcomes among patients with locally advanced esophageal cancer treated within a multidisciplinary gastro-esophageal cancer functional unit | Andrea Plaja Salarich | ![]() |
![]() |
|||
P-318 | Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit | Angelica Ferrando Díez | ![]() |
![]() |
|||
P-320 | Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database. | Johannes Uhlig | ![]() |
![]() |
|||
P-321 | The voice beyond the clinic: Delineation of young-onset cancer patient profiles using a digital social network | Ilit Turgeman | ![]() |
![]() |
|||
P-322 | Nutritional intervention impact on body mass index and toxicities related to 1st-line metastatic colorectal cancer treatment with targeted therapy | David da Silva Dias | ![]() |
![]() |
|||
P-323 | RAS mutations in metastatic colorectal cancer in central Tunisia | Melliti Rihab | ![]() |
![]() |
|||
P-324 | Advanced hepatocellular cancer: current systemic treatment sequencing and outcomes in the United States | Johannes Uhlig | ![]() |
![]() |
|||
P-325 | EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity | Loise Francisco-Anderson | ![]() |
![]() |
|||
P-326 | Chemoradiotherapy treatment in gastroesophageal junction tumors | Jesica Storino | ![]() |
![]() |
|||
P-328 | Biliary tract cancers: Epidemiology and trends in Tunisian patients | Ichrak Ben Abdallah | ![]() |
![]() |
|||
P-331 | Adjuvant chemotherapy for stage II colon cancer following complete resection: Experience of the Mohammed VI University Hospital Centre oncology center in Marrakech | kawtar El bouaouidi | ![]() |
![]() |
|||
P-332 | Real world data (RWD) study of BRAF mutant metastatic colorectal cancer (mCRC) patients (pts) across the Greater Manchester region prior to BEACON trial results | Rory Cairns | ![]() |
![]() |
|||
P-334 | Perioperative chemotherapy in the treatment of resectable and locally advanced gastric and junctional esophagogastric adenocarcinoma: Experience of a Portuguese central hospital | Ema Neto | ![]() |
![]() |
|||
P-335 | Self-reported prescribing practices in the setting of adjuvant treatment for colorectal cancer | Catherine Hanna | ![]() |
![]() |
|||
P-336 | Clinical outcomes of 49 consecutive patients admitted with malignant obstructive jaundice | Syed Abdullah Javaid Bukhari | ![]() |
![]() |
|||
P-338 | Advanced pancreatic adenocarcinoma in daily clinical practice: A single-center experience | Alaeddine SAIDI | ![]() |
![]() |
|||
P-339 | Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience | Alia Alchawaf | ![]() |
![]() |
|||
P-341 | Capecitabine/mitomycin versus 5-fluorouracil/mitomycin in combination with simultaneous integrated boost-intensity modulated radiation therapy for anal cancer | Léa Vazquez | ![]() |
![]() |
|||
P-342 | Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer | Minori Rosales | ![]() |
![]() |
|||
P-344 | The role of postoperative prognostic nutritional index as a prognostic factor and its association to systemic inflammatory response markers in stage III colon cancer | Ins Costa | ![]() |
![]() |
|||
P-345 | Evaluation of a fully automated Idylla test system for microsatellite instability in a cohort of Spanish patients with colorectal carcinoma in a single institution | Miriam Perez García | ![]() |
![]() |
|||
P-346 | Endoscopic Profiling of Various GI Malignancies in CMOSH Medical College Hospital, Chattogram, Bangladesh | Debashis Chowdhury | ![]() |
![]() |
|||
P-347 | A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients With locoregional hepatocellular carcinoma: EMERALD-1 | Bruno Sangro | ![]() |
![]() |
|||
P-348 | A multi-institutional retrospective study of stage I-IV transverse colon cancer: Diagnosis, treatment and outcome analyses | Francesca Lo Bianco | ![]() |
![]() |
|||
P-349 | Clinical significance of lymph node radio to predict prognosis in colon cancer | Gyoung Tae Noh | ![]() |
![]() |
|||
P-350 | Maintenance Trastuzumab in the setting of second line treatment in HER2 overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma: a single center experience | López López Flora | ![]() |
![]() |
|||
P-351 | RNA sequencing for personalized therapy prescription in colon cancer | Elena Poddubskaya | ![]() |
![]() |
|||
P-353 | Colorectal cancer liver metastases challenges and potential opportunities: Systematic review and meta-analysis | Ereny Saad | ![]() |
![]() |
|||
P-354 | Association Between Tumor Regression with Tumor Location and Inflammatory Biomarkers in Patients with Resectable Gastric Cancer and Gastroesophageal Junction Cancer who Underwent Perioperative Chemotherapy: Multicentric Data from Peru | Rodrigo Motta | ![]() |
![]() |
|||
P-355 | Trastuzumab-based treatment of HER2-positive metastatic gastric cancer | &304;zzet Do&287;an | ![]() |
![]() |
|||
P-356 | Phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study | Kentaro Yamazaki | ![]() |
![]() |
|||
P-357 | The Frequencies and Prognostic Significance of ABO Blood and Rhesus (D) Groups in HER2-Positive Gastric Cancer | &304;zzet Do&287;an | ![]() |
![]() |
|||
P-358 | Mutational status in Ras/Raf/MAPK signaling pathway in Moroccan colorectal cancer patients | Mohammed Sqalli Houssaini | ![]() |
![]() |
|||
P-359 | Biliary tract carcinoma: Management patterns and outcome | Ryma Boujnah | ![]() |
![]() |
|||
P-360 | EGFR-inhibitors in metastatic wild-type RAS colorectal cancer: Experience of the oncology department of Mohammed VI University Hospital in Marrakech | houda jouihri | ![]() |
![]() |
|||
P-361 | High expression levels of circulating miRNA-618 and miRNA-203a-3p are associated with prolonged survival in patients with metastatic colon cancer | Maria Radanova | ![]() |
![]() |
|||
P-362 | SIBO and lactose intolerance in patients receiving chemotherapy treatment for colorectal or gastric cancer | Nora Forones | ![]() |
![]() |
|||
P-363 | Clinical - Pathological Correlation of The Presence of Microsatellite Instability in Patients Diagnosed with Locally Advanced Gastric Adenocarcinoma from Costa Rica | Alejandra Méndez | ![]() |
![]() |
|||
P-364 | Higher amount of KRAS mutations in pre-operative plasma cell-free DNA predicts shorter survival after liver metastasectomy in colorectal cancer patients | Jiri Polivka | ![]() |
![]() |
|||
P-365 | Association between baseline serum levels of miRNA-143 and hepatocyte growth factor in patients with RAS wild type metastatic colorectal cancer treated with first-line anti-EGFR therapy | Zhasmina Mihaylova | ![]() |
![]() |
|||
P-366 | Long-term quality of life in patients treated for anal cancer: Self-reported bother of symptoms | Anna Axelsson | ![]() |
![]() |
|||
P-367 | A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries | Omkara Veeranki | ![]() |
![]() |
|||
P-368 | Primary tumor location in synchronous and metachronous liver metastases: Impact on patterns of recurrence and survival after hepatic resection | Rita Balsano | ![]() |
![]() |
|||
P-369 | Quality of life of caregivers of patients with gastrointestinal cancer | Nora Forones | ![]() |
![]() |
|||
P-372 | Safe moderate dose regimens retain full survival benefits for aged patients with and without resistant gastrointestinal cancers | Robert De Jager | ![]() |
![]() |
|||
P-373 | Moderate Dose Chemotherapy Retains Efficacy and Improves Safety in Conjunction with High Dose Ascorbic Acid (HDAA) | Howard Bruckner | ![]() |
![]() |
|||
P-384 | Quality of life and systemic pharmacokinetics of repetitive electrostatic PIPAC with oxaliplatin in patients with colorectal peritoneal metastases | Robin Lurvink | ![]() |
![]() |
|||
P-385 | A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma | Jung Hyun Jo | ![]() |
![]() |
1-4 July 2020 Barcelona
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|